Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.53 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 3/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | RARA | P10276 | 1/20 | 0.49 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7929523 | 0.96 | NR5A1 (0.55) | RARBTSHRMAPK1ALDH1A1CYP3A4 | |
| SCHEMBL7930618 | 0.94 | NR5A1 (0.58) | RARBTSHRMAPK1ALDH1A1CYP3A4 | |
| SCHEMBL10629620 | 0.92 | RARB (0.64) | RARBTSHRMAPK1ALDH1A1CYP3A4 | |
| SCHEMBL916469 | 0.92 | LTA4H (0.57) | TSHRMAPK1ALDH1A1CYP3A4SMN1; SMN2 | |
| SCHEMBL25575422 | 0.90 | KDM4E (0.50) | RARBTSHRMAPK1ALDH1A1CYP3A4 | |
| SCHEMBL7922047 | 0.90 | MAPT (0.49) | RARBTSHRMAPK1ALDH1A1CYP3A4 | |
| SCHEMBL7254241 | 0.90 | MAPT (0.51) | RARBTSHRMAPK1ALDH1A1CYP3A4 | |
| SCHEMBL11578764 | 0.90 | LTA4H (0.55) | TSHRMAPK1ALDH1A1CYP3A4SMN1; SMN2 | |
| SCHEMBL31000372 | 0.90 | LTA4H (0.55) | TSHRMAPK1ALDH1A1CYP3A4SMN1; SMN2 | |
| SCHEMBL917938 | 0.88 | NR5A1 (0.62) | TSHRLMNALTA4HDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112266392-A | Process for preparing CENICRIVIROC and related analogs | 妥必徕疗治公司 | 2021-01-26 | — | — | CN | claimed |
| EP-3237424-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | Tobira Therapeutics, Inc. (US) | 2017-11-01 | — | — | EP | claimed |
| WO-2016105527-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | TOBIRA THERAPEUTICS, INC. (US) | 2016-06-30 | — | — | WO | claimed |
| US-11839155-B2 | Organic semiconducting compounds | RAYNERGY TEK INC. (TW) | 2023-12-05 | — | — | US | disclosed |
| US-11839155-B2 | Organic semiconducting compounds | RAYNERGY TEK INC. (TW) | 2023-12-05 | — | — | US | disclosed |
| CN-112236882-B | Organic semiconductor compound | 天光材料科技股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20210171504-A1 | Purified cenicriviroc and purified intermediates for making cenicriviroc | TOBIRA THERAPEUTICS INC (US) | 2021-06-10 | — | — | US | disclosed |
| US-20210171504-A1 | Purified cenicriviroc and purified intermediates for making cenicriviroc | TOBIRA THERAPEUTICS INC (US) | 2021-06-10 | — | — | US | disclosed |
| CN-112266392-A | Process for preparing CENICRIVIROC and related analogs | 妥必徕疗治公司 | 2021-01-26 | — | — | CN | disclosed |
| US-20200216476-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | TOBIRA THERAPEUTICS INC (US) | 2020-07-09 | — | — | US | disclosed |
| US-20200216476-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | TOBIRA THERAPEUTICS INC (US) | 2020-07-09 | — | — | US | disclosed |
| WO-2016105527-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | TOBIRA THERAPEUTICS, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| EP-2818531-A1 | Polymerisable compounds and the use thereof in liquid-crystal displays | Merck Patent GmbH (DE) | 2014-12-31 | — | — | EP | disclosed |
| US-20140375943-A1 | POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | MERCK PATENT GMBH (DE) | 2014-12-25 | — | — | US | disclosed |
| US-20050107606-A1 | Process for producing optically active sulfoxide derivative | TATKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | disclosed |
| EP-1484322-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SULFOXIDE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2004-12-08 | — | — | EP | disclosed |
| EP-1211239-A1 | PROCESS FOR THE PREPARATION OF 2,3-DIHYDROAZEPINE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2002-06-05 | — | — | EP | disclosed |
| EP-1140896-A1 | BENZOTHIEPIN-ANILIDE DERIVATIVES, THEIR PRODUCTION AND THEIR USE FOR ANTAGONIZING CCR-5 | Takeda Chemical Industries, Ltd. (JP) | 2001-10-10 | — | — | EP | disclosed |
| US-6235771-B1 | AIDS THERPAY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| WO-2000037455-A1 | BENZOTHIEPIN-ANILIDE DERIVATIVES, THEIR PRODUCTION AND THEIR USE FOR ANTAGONIZING CCR-5 | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11839155-B2 | Organic semiconducting compounds | OCIAD2, OCIAD1, OSTC | RARB 1800/4885TSHR 4717/4885MAPK1 2031/4885 |
| US-20050107606-A1 | Process for producing optically active sulfoxide derivative | CCR5, OPRM1, CXCR4 | RARB 274/4885TSHR 1153/4885MAPK1 650/4885 |
| US-20200216476-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | CCR5, CCR2, CCR3 | RARB 2241/4885TSHR 3282/4885MAPK1 106/4885 |
| US-20210171504-A1 | Purified cenicriviroc and purified intermediates for making cenicriviroc | CCR5, CCR2, CXCR3 | RARB 3053/4885TSHR 4134/4885MAPK1 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.